Two major transactions reinforced a broader 2026 pattern of Big Pharma paying for late-stage or near-late-stage oncology and immunotherapy platforms. In one deal stream, Incyte’s Vega acquisition brings a Phase III bleeding disorder program into the hematology portfolio and follows repeated moves to fill growth after patent cliff dynamics. In parallel, Johnson & Johnson agreed to acquire Firefly Bio for $1 billion in cash, targeting degrader-antibody conjugates (DACs) for KRAS-driven solid tumors. J&J’s interest centers on delivering degradation biology with antibody targeting to expand beyond limitations of standard ADC payload release. Key takeaway: the combined moves show pharma prioritizing registrational timing and platform differentiation—especially in oncology hard-to-drug targets.